Curagen (CRGN) was one of few winners of Tuesday's session. Earlier, BWS Financial upgraded the stock to strong buy from buy. Curagen was adding 44 cents, or 12.4%, to $4.
Oscient Pharmaceuticals (OSCI) was also higher after posting a narrower-than-expected fourth-quarter loss, thanks to sales of the company's Antara cardiovascular drug. Shares of Oscient were up 15 cents, or 3%, to $5.10.
Threshold (THLD - Get Report) plummeted 57.5% after the company said late Monday that a phase III clinical trial of its drug glufosfamide failed to show the ability to extend the lives of patients with advanced pancreatic cancer. Threshold was down $2.06 to $1.52.